Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $123.22.

ZBH has been the topic of a number of research analyst reports. Evercore ISI cut their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Raymond James lowered their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. BTIG Research lowered their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Truist Financial lifted their price objective on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a report on Friday, November 1st. Finally, TD Cowen lowered their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZBH. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the 3rd quarter worth $31,000. Family Firm Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter worth $33,000. Finally, Brooklyn Investment Group purchased a new stake in Zimmer Biomet during the 3rd quarter worth $35,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.0 %

Zimmer Biomet stock opened at $108.40 on Wednesday. Zimmer Biomet has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market cap of $21.58 billion, a PE ratio of 20.61, a PEG ratio of 1.99 and a beta of 1.02. The business’s 50-day simple moving average is $107.55 and its two-hundred day simple moving average is $108.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the prior year, the firm earned $1.65 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. Equities analysts anticipate that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.